Novelty Nobility Inc.
Seoul, South Korea
Program data pending ClinicalTrials.gov matching
57.5
Signal Score
○ FDA Inspections
○ Clinical Trials
○ SEC Filings
✓ Press (1)
○ EMA GMP
○ MHRA GMP
Quick Facts: Novelty Nobility Inc.
- Signal Score
- 57.5/100
- Quality Compliance
- Assessment pending
- Headquarters
- Seoul, South Korea
- Modalities
- Monoclonal Antibody, Bispecific Antibody, Antibody-Drug Conjugate (ADC)
- Active Programs
- No ClinicalTrials.gov matches confirmed
- Data Sources
- FDA Data Dashboard, ClinicalTrials.gov, SEC EDGAR, press monitoring
- Scored By
- CDMO Signal — independent CDMO intelligence platform
About Novelty Nobility Inc.
Auto-created by AI matchmaker. Data verification pending.
Signal Score & Pillar Breakdown
Quality Compliance
—
No FDA inspection records found. This CDMO may operate under a different legal name or may not have US FDA-inspected facilities.
FDA InspectionsNo US records on file
No FDA inspection records found for this manufacturer
Quality score requires FDA inspection data
Operations
—
No ClinicalTrials.gov facility matches confirmed for this manufacturer.
Programs
— no verified data
Sponsors— no verified data
ModalitiesMonoclonal Antibody, Bispecific Antibody, Antibody-Drug Conjugate (ADC)
No clinical trial matches found for this manufacturer
Operational score requires ClinicalTrials.gov data
Data sourced from ClinicalTrials.gov, FDA, SEC EDGAR, and verified press only. No unverified estimates shown.
Financial Stability
60.0
Private company
Financial assessment: 60.0/100
Source: SEC EDGAR, press monitoring
Profile-based financial assessment
SEC FilingsPrivate company
Private company
Financial assessment: 60.0/100
Capacity
55.0
Manufacturing site information being gathered
Modalities: Monoclonal Antibody, Bispecific Antibody, Antibody-Drug Conjugate (ADC)
Capacity assessment: 55.0/100
Source: SEC EDGAR, press monitoring, company profiles
Profile-based capacity assessment
Recent Press1 articles
Manufacturing site information being gathered
Modalities: Monoclonal Antibody, Bispecific Antibody, Antibody-Drug Conjugate (ADC)
Capacity assessment: 55.0/100
Recent News 1 articles
AGC Biologics & Novelty Nobility Partner for Cell Line Development - Contract Pharma
Frequently Asked Questions About Novelty Nobility Inc.
What is Novelty Nobility Inc.'s CDMO Signal Score?
Novelty Nobility Inc. has a Signal Score of 58/100, based on quality, operations, financial stability, and capacity data.
Evaluating Novelty Nobility Inc. for a manufacturing program?
Use the free AI matchmaker to compare Novelty Nobility Inc. against other CDMOs by FDA, EMA, and clinical-trial data — no login required.
Find & compare CDMOs →
Represent this organization? Contact us to verify or update this profile.
See all CDMOs in:
Similar CDMOs
Boehringer Ingelheim BioXcellence
Ingelheim am Rhein, Germany
Monoclonal Antibody, Bispecific Antibody, Recombinant Protein, Antibody Fragments, Biosimilars, Biologics
Kemwell Biopharma
Bengaluru, India
Monoclonal Antibody, Bispecific Antibody, Recombinant Protein, Biosimilars, Cell Therapy, Sterile Fill-Finish
Kemwell Biopharma, Bangalore
Bengaluru, India
Monoclonal Antibody, Bispecific Antibody, Recombinant Protein, Biosimilars, Cell Therapy, Sterile Fill-Finish, Lyophilized Drug Product
AsymBio
Shanghai, China
Monoclonal Antibody, Bispecific Antibody, Recombinant Protein, ADC, Bioconjugates (NDC, RDC, AOC, PDC, BsADC), Plasmid DNA, mRNA, Fill-Finish
Healsun Biopharm (Hangzhou Healsun Biopharm Co., Ltd.)
Hangzhou, China
Monoclonal Antibody, Recombinant Protein, Bispecific Antibody, Fusion Protein, ADC, XDC (ADC, RDC, Bioconjugates), Cell Line Development (CHO)